Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New Press Release - Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

<< Previous

Bullboard Posts

Next >>

Comment by Snowdrifton Feb 28, 2024 4:57pm

97 Views

Post# 35904941

RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

I just found the info on LinkedIn. It doesn't mention the time, but it does list Oncolytics for March 1.

https://www.linkedin.com/posts/cancer-advocacy-group-of-louisiana-cagla_neauxcancer2024-activity-7157118500849774592-513G

Snowdrift wrote: Thanks for clarifying, but where did you see that? There's no mention of the Acadia room in the agenda.

itntdf wrote:
he appears in the "investment track" acadia room in the 10:30-11 time slot in the 1st.